HALO - Antares Pharma stock soars 44% on potential ~$1B acquisition deal by Halozyme - WSJ

Halozyme Therapeutics (NASDAQ:HALO) is nearing a deal to acquire Antares Pharma (NASDAQ:ATRS) for ~960M, The Wall Street Journal reported citing people familiar with the matter. The deal could be announced today, April 13. Shares of Antares rose +44.39% to $5.40 pre-market April 13. San Diego-based Halozyme will pay $5.60 per share in cash, valuing the Ewing, N.J.-based Antares at about $960M, said the report. Antares develops therapeutic products using its drug delivery systems. In March, the company received full FDA approval for its oral testosterone replacement therapy TLANDO. The company has plans to launch the drug in Q2 this year. Halozyme already owns a drug-delivery product called Enhanze and has licensing deal with Pfizer and Bristol-Myers Squibb, among others, said the report.

For further details see:

Antares Pharma stock soars 44% on potential ~$1B acquisition deal by Halozyme - WSJ